On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines, published COVAXﾒs first round of allocations.

The first round of allocation outlined delivery of doses of the AZ/Oxford vaccine ﾖ manufactured by AstraZeneca (AZ) and COVISHIELD, licensed to and manufactured by Serum Institute of India (SII/AZ) ﾖ to Facility participants, through May 2021.

This first round of allocation outlines delivery of doses of the AZ/Oxford vaccine – manufactured by AstraZeneca (AZ) and COVISHIELD, licensed to and manufactured by Serum Institute of India (SII/AZ) – to Facility participants. Participants not listed have either exercised their rights to opt-out of this vaccine, wish to transfer allocated doses to AMC participants, are AMC-eligible but have not joined the AMC, have voluntarily delayed receipt of doses and communicated this intent ahead of allocation, or have not met financial requirements.

This list will be updated by the end of the week to provide indicative timelines for the supply of these doses, split into Feb-March and April-May. These timelines are dependent on a variety of factors including national regulatory requirements, availability of supply, and fulfilment of other criteria such as validated national deployment and vaccination plans (NDVPs) from AMC participants, indemnification & liability agreements, and export and import authorisations.

In addition to this first round of allocations, an exceptional distribution of 1.2 million doses of the Pfizer-BioNTech vaccine, anticipated for delivery in Q1 2021, was announced in early February.